Portman Square Capital LLP Abb Vie Inc. Call Options Transaction History

Portman Square Capital LLP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Jul 19, 2024	SELL	$154.79 - $180.76 $3.71 Million - $4.34 Million	-24,000 Reduced 68.38%	11,100 $1.9 Million
Q1 2024 Apr 15, 2024	SELL	$159.82 - $182.1 $1.42 Million - $1.62 Million	-8,900 Reduced 20.23%	35,100 $6.39 Million
Q4 2023 Jan 19, 2024	BUY	$137.6 - $154.97 $2.08 Million - $2.34 Million	15,100 Added 52.25%	44,000 $6.82 Million
Q2 2023 Jul 26, 2023	BUY	$132.51 - $164.9 $2.16 Million - $2.69 Million	16,300 Added 129.37%	28,900 $3.89 Million
Q1 2023 May 04, 2023	BUY	$144.61 - $166.54 $636,284 - $732,776	4,400 Added 53.66%	12,600 $2.01 Million
Q4 2022 Feb 23, 2023	BUY	$138.31 - $165.87 $1.13 Million - $1.36 Million	8,200 New	8,200 $1.33 Billion

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $317B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Portman Square Capital LLP, based on Form 13F filings with the SEC.

Stay updated on Portman Square Capital LLP with notifications on news.